Sequent Scientific Ltd (VIYASH) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a strong quarter with healthy double-digit year-on-year revenue growth of 15%, driven by robust performance across all business geographies, particularly in the formulations segment.
- Profitability saw a significant improvement, with a 270 basis points increase in gross margin and a 330 basis points expansion in the pre-ESOP EBITDA margin to 15.5%, successfully achieving the company's near-term target.
- The company received the final approval from the National Company Law Tribunal (NCLT) for the merger with Vyas Life Sciences, marking a significant milestone that is expected to unlock substantial synergies and drive future growth.
- The formulations business, contributing 75% of sales, grew by 18% YoY, with Europe showing a 14% YoY growth and emerging markets delivering a strong 27% YoY growth, supported by a new front-end presence in Mexico.
- The API business demonstrated a positive transformation, clocking a 7% YoY growth and commercializing a new API partnership with a launch in the US, reinforcing its position as a reliable, high-quality partner.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.